Heterocyclic derivatives as nav1.7 and nav1.8 blockers
KR20200135834A
Condensed cyclic urea derivatives as CRHR2 antagonists
US2020230123A1
Biaryloxy derivatives as ttx-s blockers
CN110612285A
Amide derivatives as Nav1.7 and Nav1.8 blockers
US2020405706A1
Tetrahydroquinoline derivatives as p2x7 receptor antagonists
US2018305341A1
Imidazolinone derivatives as trpm8 antagonists
WO2016067638A1
Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
EP3131916A1
Serine derivatives as ghrelin receptor agonists
CN108329305A
Benzo isoxazole derivative salt
TW201625248A
5-ht4 receptor agonist for gastroparesis
MX2016011632A
Azaspiro derivatives as trpm8 antagonists.
CA2910123A1
Polymorph form of 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-l-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide l-tartrate
KR20150085515A
Polymorph forms
EP2914597A1
Pyrazolopyridine derivatives as ttx-s blockers
WO2013175805A1
Ghrelin receptor agonists for the treatment of achlorhydria
BR112014026399A2
compound of formula (i) and formula (ii), pharmaceutical composition, method for treating a condition or disorder in which ttx-s channel blockers are involved in an animal, including a human, use and process for preparing a composition pharmaceutical
CA2871229A1
Pyrrolopyridinone derivatives as ttx-s blockers
CN103889414A
Medicinal composition
KR20140041524A
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
CN108159048A
5-HT4 receptor stimulating agents as dynamics-promoting medicine
